3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
2
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Other hematologic neoplasm
1
Lymphoid
1
Classical hematology
1
Breast
1
Conditions
Anemia
43
Anemia, Refractory, with Excess of Blasts
40
Leukemia, Myeloid, Acute
38
Myelodysplastic Syndromes
36
Leukemia
34
Neoplasms
29
Precursor Cell Lymphoblastic Leukemia-Lymphoma
27
Multiple Myeloma
25
Thrombocytopenia
23
Leukemia, Lymphocytic, Chronic, B-Cell
21
Primary Myelofibrosis
20
Lymphoma
20
Lymphoma, Non-Hodgkin
19
Leukemia, Myelomonocytic, Chronic
18
Venous Thromboembolism
17
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
16
Hodgkin Disease
16
Myeloproliferative Disorders
15
Lymphoma, Mantle-Cell
14
Anemia, Aplastic
14
Anemia, Refractory
13
Lymphoma, Follicular
12
Hematologic Neoplasms
12
Lymphoma, Large B-Cell, Diffuse
11
Congenital Abnormalities
10
Neoplasms, Plasma Cell
9
Myelodysplastic-Myeloproliferative Diseases
9
Lymphoma, Large-Cell, Immunoblastic
9
Leukemia, Myeloid, Chronic-Phase
9
Burkitt Lymphoma
9
Interventions
eltrombopag
1
Cytarabine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
Pathologic Complete Response
×
Classical hematology
×
Clear all
NCT01656252
2020-11-03
PrE0901
PrECOG, LLC.
Phase 1/2
Terminated
15 enrolled
5 charts